TSU-68 (Random Configuration)
| Title | Journal |
|---|---|
| A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. | Investigational new drugs 20120801 |
| The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. | Bioorganic & medicinal chemistry letters 20120801 |
| Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. | Bioorganic & medicinal chemistry 20120715 |
| N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. | Bioorganic & medicinal chemistry 20120401 |
| Augmentation of chemotherapeutic infusion effect by TSU-68, an oral targeted antiangiogenic agent, in a rabbit VX2 liver tumor model. | Cardiovascular and interventional radiology 20120201 |
| Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120201 |
| Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. | Journal of gastroenterology 20120101 |
| Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity. | Journal of medicinal chemistry 20110609 |
| Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. | Cancer chemotherapy and pharmacology 20110501 |
| Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. | Cancer chemotherapy and pharmacology 20110501 |
| A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. | Cancer chemotherapy and pharmacology 20110201 |
| Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. | Bioorganic & medicinal chemistry 20100515 |
| 5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases. | Bioorganic & medicinal chemistry letters 20090201 |
| TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. | Surgery today 20090101 |
| TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. | Cancer research 20081201 |
| Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68). | Drug metabolism and disposition: the biological fate of chemicals 20080601 |
| Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68. | Drug metabolism and pharmacokinetics 20080101 |
| The selectivity of protein kinase inhibitors: a further update. | The Biochemical journal 20071215 |
| Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats. | Drug metabolism and disposition: the biological fate of chemicals 20070901 |
| Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. | Bioorganic & medicinal chemistry letters 20070901 |
| Potent platelet-derived growth factor-beta receptor (PDGF-betaR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one derivatives. | Chemical & pharmaceutical bulletin 20070201 |
| Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050901 |
| Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). | International journal of cancer 20050320 |
| Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050315 |
| Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. | Journal of neurosurgery 20050201 |
| Combined antiangiogenic and immune therapy of prostate cancer. | Angiogenesis 20050101 |
| In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040115 |
| Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. | Journal of medicinal chemistry 20030327 |
| Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. | Journal of medicinal chemistry 19991216 |